Challenges With Stopping Long-term Nucleos(t)ide Analogue Therapy in Patients With Chronic Hepatitis B

Gastroenterology. 2020 Apr;158(5):1185-1190. doi: 10.1053/j.gastro.2019.10.050. Epub 2019 Dec 4.

Authors

K Seng Liem¹, Adam J Gehring², Jordan J Feld³, Harry L A Janssen²

Affiliations

¹ Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada; Department of Gastroenterology and Hepatology, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands.
² Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada.
³ Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada; McLaughlin-Rotman Centre for Global Health, Toronto, Ontario, Canada.

PMID: 31809724
DOI: 10.1053/j.gastro.2019.10.050

No abstract available

Publication types

Editorial

MeSH terms

Antiviral Agents / administration & dosage*
Antiviral Agents / adverse effects
Carcinoma, Hepatocellular / pathology
Carcinoma, Hepatocellular / prevention & control
Carcinoma, Hepatocellular / virology
Consensus
Disease Progression
Drug Administration Schedule
Evidence-Based Medicine / standards
Gastroenterology / standards
Hepatitis B virus / isolation & purification*
Hepatitis B, Chronic / drug therapy*
Hepatitis B, Chronic / pathology
Hepatitis B, Chronic / virology
Humans
Liver Failure / pathology
Liver Failure / prevention & control
Liver Failure / virology
Liver Neoplasms / pathology
Liver Neoplasms / prevention & control
Liver Neoplasms / virology
Nucleosides / administration & dosage*
Nucleosides / adverse effects
Nucleosides / analogs & derivatives
Practice Guidelines as Topic
Time Factors
Treatment Outcome

Substances

Antiviral Agents
Nucleosides